Clinical Trials in Austria: Academic Excellence and Central European Access

Why Sponsors Choose Austria for Clinical Trials

Austria offers a combination of strong academic sites and central European positioning. Sponsors typically include Austria when:

• The programme covers the German-speaking European region alongside Germany and Switzerland
• Vienna’s Medical University or AKH Wien is a target site for a specific indication
• The therapeutic area has strength at Austrian medical universities (oncology, neurology, rare diseases)
• The sponsor wants EU membership combined with German-language research traditions
• Phase II or early Phase III studies benefit from concentrated patient populations at Vienna’s large academic hospitals

Austria is less suited as a primary enrolment country for large Phase III trials due to its smaller patient pool, and the multi-committee ethics structure can add administrative overhead for multi-site studies. It works best as a complementary country in broader European programmes.

Regulatory Framework for Clinical Research in Austria

Austria fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and processes all interventional clinical trial applications via CTIS. The national competent authority is BASG (Bundesamt für Sicherheit im Gesundheitswesen), which is responsible for the scientific and safety assessment of clinical trial applications.

Austria’s ethics review system is decentralised, with nine Bundesländer each maintaining their own ethics committees. For multi-site trials involving sites in multiple states, sponsors must coordinate with the relevant state ethics committees, which adds administrative complexity compared to countries with a single national committee. The EU CTR’s Part II review framework provides some structure for this process, but sponsors should plan for multi-committee coordination from the outset.

German-language documentation is required for certain ethics submission elements, including patient information and informed consent forms for Austrian sites. Sponsors running German-language programmes (covering Germany, Austria, and Switzerland) can leverage shared translation efforts, but Austrian German and Swiss German have minor variations that sometimes require localisation.

Clinical Trial Approval Process in Austria (Step-by-Step)

• Step 1 – CTIS submission: Sponsor submits via CTIS. Austria can act as Reporting Member State or Member State Concerned.
• Step 2 – Validation: CTIS validates the dossier. German-language patient documents must be included.
• Step 3 – Part I assessment (BASG): BASG conducts the scientific and safety review of the IMP and trial protocol.
• Step 4 – Part II assessment (state ethics committee): The relevant state ethics committee (or committees, for multi-site trials) reviews the ethical aspects. Vienna’s ethics committee (Ethikkommission der Medizinischen Universität Wien) typically handles the lead review for Vienna-based trials.
• Step 5 – RFI (if applicable): Either BASG or the ethics committee may issue an RFI. German-language queries are common from state ethics committees.
• Step 6 – Authorisation and site activation: BASG issues the decision via CTIS. Site contracting follows, with additional coordination needed for multi-state sites.

Clinical Trial Approval Timeline in Austria (How Long It Takes)

Austria’s approval timelines are in the mid-range for EU countries. The main complexity for multi-site programmes is the multi-committee ethics structure. For single-site Vienna programmes, timelines are more predictable:

Step	Estimated Timeline
CTIS submission and validation	1–7 working days
BASG Part I assessment	~45–60 days
State Ethics Committee Part II assessment	~45–60 days (parallel)
RFI response period (if applicable)	12–31 days (clock stopped)
Site contract and budget negotiation	6–16 weeks
Estimated total from submission to first patient	~4–6 months

For programmes involving sites in multiple Austrian states, add 4–8 additional weeks for multi-ethics committee coordination. Sponsors should plan for German-language RFI responses and ensure that German-language document preparation is part of the standard workflow.

Clinical Trial Sites in Austria

Austria’s clinical trial infrastructure is centred on its three medical universities and their associated hospitals:

• Medical University of Vienna / AKH Wien (Allgemeines Krankenhaus der Stadt Wien) – Austria’s flagship academic hospital and medical university; one of the largest hospitals in Europe by capacity. Active in oncology, haematology, neurology, cardiology, gastroenterology, and transplantation. AKH Wien is the primary target site for most Austrian clinical trial programmes.
• Medical University of Graz / LKH Universitätsklinikum Graz – The Styrian university hospital; strong in oncology, cardiology, gastroenterology, and endocrinology. Second most active Austrian trial site.
• Medical University of Innsbruck / Universitätsklinik Innsbruck – Tyrolian medical university hospital; active in oncology, neurology, and rheumatology. Serves as a site for trials targeting Western Austria.
• Kepler University Hospital Linz – Upper Austria’s university hospital; active in oncology, gastroenterology, and nephrology. A growing research centre.

Vienna dominates Austrian clinical trial activity. For most sponsors, AKH Wien is the essential Austrian site, with Graz as a secondary option for additional patient access.

Patient Recruitment in Austria

Austria’s social health insurance system (Sozialversicherung) provides universal healthcare coverage and creates relatively centralised patient flows through the major academic hospitals. Vienna, with roughly 2 million residents in the metropolitan area, provides a substantial catchment for AKH Wien. For oncology and rare disease indications, national referral networks channel eligible patients to Vienna and Graz.

For rare diseases, Austria’s academic centres maintain specialist registries and participate in European Reference Networks (ERNs), facilitating identification of eligible patients. Patient recruitment is generally reliable at the major academic sites for indications with established referral pathways, though the national patient pool is smaller than in Germany.

Therapeutic Areas with Strong Clinical Trial Activity in Austria

• Oncology and haematology – Austria’s most active area; AKH Wien and LKH Graz participate in major international oncology networks
• Neurology and neurodegenerative diseases – Active Alzheimer’s, multiple sclerosis, and Parkinson’s programmes; Medical University of Vienna has strong neuroscience output
• Rare diseases – ERN-affiliated centres; Lysosomal Disease Network and other rare disease research active at AKH Wien and Innsbruck
• Cardiovascular medicine and cardiology – Strong research output at AKH Wien and LKH Graz
• Gastroenterology – Active programmes at AKH Wien and Graz; inflammatory bowel disease research is particularly strong

Clinical Trial Start-Up Timelines in Austria

Start-up in Austria is moderately efficient for Vienna-focused programmes. Multi-site programmes involving multiple states carry additional ethics coordination overhead. Typical ranges:

Activity	Estimated Duration
Regulatory and ethics approval (CTIS)	45–60 days
Site contract and budget negotiation	6–14 weeks
Multi-state ethics coordination (if applicable)	4–8 additional weeks
Site initiation visit and staff training	2–4 weeks
First patient screened	~4–7 months from submission

Costs of Conducting a Clinical Trial in Austria

Austria is in the moderate-to-high cost range for European clinical research, broadly comparable to Germany. Investigator fees, research staff salaries, and hospital overhead charges reflect Austrian wage levels, which are higher than Central and Eastern European comparators. Per-patient costs for a Phase II oncology trial typically range from €18,000 to €42,000.

German-language document translation and multi-state ethics committee fees should be budgeted. Austria’s social health insurance covers standard-of-care elements for trial participants, reducing the per-patient charge to sponsors for hospitalisation and routine procedures.

When Austria Is the Right Choice for Clinical Trials

Austria is most appropriate when:

• The programme covers the German-speaking European region and Austria adds geographic diversity
• AKH Wien or Medical University of Vienna is a target site for investigator expertise or patient access
• The indication has strength at Austrian academic centres – particularly oncology, neurology, or rare diseases
• EU membership is required (distinguishing Austria from Switzerland for regulatory purposes)

Austria is less suitable as a primary enrolment country and is best used as a quality supplementary site in a broader European programme.

Advantages of Conducting Clinical Studies in Austria

• Full EU membership and CTIS integration under the EU CTR
• AKH Wien is one of Europe’s largest and most experienced academic trial sites
• Three medical universities providing geographically distributed academic research capacity
• Universal healthcare coverage ensuring consistent patient access to academic hospitals
• ERN-affiliated rare disease centres at major academic hospitals
• Central European location with access to Germany and the broader DACH region

How APICES Supports Clinical Trials in Austria

APICES provides end-to-end CRO support for clinical trials in Austria, including CTIS regulatory submissions, BASG liaison, state ethics committee coordination, site identification, feasibility assessment, and site management. We have experience navigating Austria’s multi-committee ethics structure and can manage German-language document preparation and regulatory communications.

For sponsors running DACH-region programmes (Germany, Austria, Switzerland), APICES provides integrated oversight across all three countries. Our Austrian team maintains working relationships with AKH Wien, Medical University of Graz, and other principal sites, enabling efficient contracting and initiation.

Frequently Asked Questions About Clinical Research in Austria

How long does clinical trial approval take in Austria?
Austria processes interventional clinical trial applications via CTIS under the EU CTR. BASG conducts the Part I scientific and safety assessment in parallel with the relevant state ethics committee’s Part II review. For a complete, well-prepared dossier, the combined decision typically falls within 45–60 days. Austria sits in the middle of the EU range for approval speed – not as fast as Denmark or Sweden, but not among the slowest. For multi-site programmes involving sites in different Austrian states, coordination across multiple ethics committees adds time, and sponsors should factor in 4–8 additional weeks for this coordination.

Who is the competent authority for clinical trials in Austria?
BASG (Bundesamt für Sicherheit im Gesundheitswesen) is Austria’s national competent authority, responsible for the scientific and safety review of clinical trial applications. Ethics review is decentralised across Austria’s nine Bundesländer, each of which maintains a separate ethics committee. For trials at Vienna sites, the Ethikkommission der Medizinischen Universität Wien typically serves as the lead ethics committee. For trials across multiple states, additional state ethics committees are involved in the Part II review.

What language is required for patient documents in Austria?
All patient-facing documents must be prepared in German. This includes informed consent forms, patient information sheets, recruitment materials, and any patient questionnaires or diaries. Some Austrian state ethics committees request minor adaptations to standard German-language documents to reflect Austrian usage; sponsors running DACH-region programmes (Germany, Austria, Switzerland) should plan for Austrian localisation of shared German-language materials. Research staff and investigators at Austria’s major academic hospitals communicate fluently in English for international trial operations.

What are the main clinical trial sites in Austria?
AKH Wien (Allgemeines Krankenhaus der Stadt Wien), linked to the Medical University of Vienna, is Austria’s flagship academic hospital and most active trial site. It is one of the largest hospitals in Europe and participates in major international oncology, haematology, neurology, and cardiovascular networks. LKH Universitätsklinikum Graz (Medical University of Graz) is the principal Styrian site, particularly strong in oncology and cardiology. Medical University of Innsbruck serves Western Austria, and Kepler University Hospital Linz is a growing research centre for Upper Austria.

Does Austria have multiple ethics committees for clinical trials?
Yes – Austria’s decentralised ethics review structure is the most significant administrative complexity for multi-site Austrian programmes. Each of Austria’s nine Bundesländer maintains its own ethics committee, and trials involving sites in multiple states must engage with the relevant committee in each state. Under the EU CTR Part II framework, this is managed through CTIS, but coordination between multiple committees can add time and complexity. For most international sponsors, keeping Austrian participation to Vienna-based sites (covered by a single ethics committee) simplifies the process considerably.

What does a Phase II oncology trial cost per patient in Austria?
Per-patient costs for a Phase II oncology trial in Austria typically range from €18,000 to €42,000, broadly comparable to Germany. This range reflects differences in protocol complexity, visit frequency, imaging and laboratory requirements, and site-specific overhead charges. German-language document translation and multiple state ethics committee fees should be budgeted separately. Austria’s Sozialversicherung (social health insurance) covers standard-of-care costs for trial participants in most cases, which reduces the sponsor’s per-patient charge for hospitalisation and routine procedures.